Rani Therapeutics Holdings, Inc. Class A Common Stock
RANI
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Last trade$0.5668
Day change+$0.0265 (+4.90%)
Day range$0.531 – $0.599
Volume462,342
Market cap$62M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$62.36M
Price / earnings
—
Price / book
1.84×
Price / sales
9.47×
EV / sales
8.92×
EV / EBITDA
-1.71×
Profitability
Earnings per share
-$0.28
Return on assets
-61.79%
Return on equity
-95.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.26×
Quick ratio
5.26×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RANI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.71M
$1.71M
$1.71M
$1.46M
$0
$0
$172K
$1.03M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.71M
$1.71M
$1.71M
$1.46M
$0
$0
$172K
$1.03M
Selling, general and administrative
$4.91M
$5.52M
$4.89M
$5.09M
$4.04M
$5M
$5.62M
$5.46M
Research and development
$6.02M
$5.02M
$5.16M
$4.91M
$3.22M
$5.51M
$6.57M
$6.81M
Total operating expenses
$10.93M
$10.54M
$10.05M
$10M
$7.26M
$10.51M
$12.19M
$15.99M
Operating income
-$9.22M
-$8.83M
-$8.34M
-$8.54M
-$7.26M
-$10.51M
-$12.01M
-$14.96M
Interest expense
-$43K
-$8K
-$88K
-$347K
-$725K
-$877K
-$943K
-$1.12M
Income before taxes
-$8.81M
-$8.42M
-$8.02M
-$9.07M
-$7.91M
-$11.22M
-$12.74M
-$15.72M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.81M
-$8.42M
-$8.02M
-$9.07M
-$7.91M
-$11.22M
-$12.74M
-$15.72M
Net income attributable to common shareholders
-$7.73M
-$7.39M
-$7.03M
-$10.31M
-$5.41M
-$6.69M
-$7.26M
-$8.95M
EBITDA
-$9.1M
-$8.68M
-$8.18M
-$8.35M
-$7.03M
-$10.27M
-$11.76M
-$10.98M
Basic earnings per share
-$0.04
-$0.04
-$0.04
-$0.07
-$0.12
-$0.18
-$0.22
-$0.27
Diluted earnings per share
-$0.04
-$0.04
-$0.04
-$0.07
-$0.12
-$0.18
-$0.22
-$0.27
Recent news
Company coverage with links to the original publishers.
Rani Therapeutics announced a $20 million registered direct offering of Class A common stock at $1.07 per share, along with pre-funded warrants, led by a sovereign wealth fund and other healthcare-focused investors. The offering is expected to close on May 27, 2026. The company is a clinical-stage biotherapeutics firm developing oral delivery technologies for biologics.
Rani Therapeutics announced the appointment of Jesper Høiland as Head of Strategy, a newly created role. Høiland, who has served as a strategic adviser since 2023, brings over 30 years of pharmaceutical leadership experience, including expertise in obesity and metabolic disease. He will be responsible for shaping corporate and pipeline strategy, prioritizing internal programs, and supporting partnering efforts. Previously, Høiland held senior positions at Ascendis Pharma, Radius Health, and Novo Nordisk.
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.